caa a22 4500 388111321 CHVBK 20180307125354.0 cr unu---uuuuu 161130e199906 xx s 000 0 eng 10.1017/S0924270800036218 doi S0924270800036218 pii (NATIONALLICENCE)cambridge-10.1017/S0924270800036218 Tibben A. Coping with genetic burden [Elektronische Daten] [A. Tibben] An increasing number of neurodegenerative diseases have been defined at the molecular level in recent years, making it possible to determine precisely the genotype before the onset of symptoms. Pre-symptomatic testing programs are available for Huntington disease (HD), hereditary cerebral haemorrhage with amyloid-Dutch type, inherited cerebral ataxia, myotonic dystrophy, and Alzheimer disease. Although treatment options such as gene therapy have no widespread application until now, and much has to be developed, the use of predictive DNA-diagnostics has become a clinical application for a number of hereditary diseases. For psychiatric disorders such as schizophrenia or bipolar disorders, there are indications for localisation of the genetic factors, but clinical use of genetics is still far from reality. Yet, the increasing knowledge about genetics will have far-reaching influence in most fields of modern medicine and in health care provisions. Copyright © Scandinavian College of Neuropsychopharmacology 1999 Coping nationallicence Huntington disease nationallicence predictive testing nationallicence presenile dementia nationallicence risk perception nationallicence Acta Neuropsychiatrica Cambridge University Press 11/2(1999-06), 74-76 0924-2708 11:2<74 1999 11 NEU https://doi.org/10.1017/S0924270800036218 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1017/S0924270800036218 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Tibben A. NATIONALLICENCE 773 0- Acta Neuropsychiatrica Cambridge University Press 11/2(1999-06), 74-76 0924-2708 11:2<74 1999 11 NEU CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-cambridge